Theravance Reports Positive Phase II Results For Chronic Constipation Therapy TD-5108
This article was originally published in The Pink Sheet Daily
Executive Summary
Specificity of the 5-HT4 agonist gives it a better cardiovascular safety profile than withdrawn Novartis product Zelnorm, Theravance VP-Development Kitt says.
You may also be interested in...
GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.
GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.
Zelnorm Will Be Available Under Treatment IND Following Marketing Suspension
Novartis voluntarily suspends marketing of the irritable bowel syndrome medication due to cardiovascular events.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: